The potential role of cannabinoids in dermatology.

 Publication Cover“Cannabis is increasingly being used world-wide to treat a variety of dermatological conditions. Medicinal cannabis is currently legalized in Canada, 31 states in America and 19 countries in Europe. The authors reviewed the literature on the pharmacology and use of cannabinoids in treating a variety of skin conditions including acne, atopic dermatitis, psoriasis, skin cancer, pruritus, and pain. Cannabinoids have demonstrated anti-inflammatory, antipruritic, anti-ageing, and antimalignancy properties by various mechanisms including interacting with the newly found endocannabinoid system of the skin thereby providing a promising alternative to traditional treatments.”

https://www.ncbi.nlm.nih.gov/pubmed/31599175

https://www.tandfonline.com/doi/abs/10.1080/09546634.2019.1675854?journalCode=ijdt20

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

[Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus].

“Chronic, therapy-resistant pruritus often fails to respond to standard measures so new therapeutic approaches are needed.

Recently, the expression of cannabinoid receptors on cutaneous sensory nerve fibers was described, so cannabinoid agonists seem a rational therapeutic option for pruritus.

RESULTS:

In 14/22 patients a good antipruritic effect could be documented. The average reduction in itch was 86.4%. The therapy was well-tolerated by all patients; neither burning burn nor contact dermatitis was observed.

CONCLUSIONS:

Topical cannabinoid agonists represent an new effective and well-tolerated therapy for refractory itching of various origins. Creams with a higher concentration may be even more effective with broader indications.”

https://www.ncbi.nlm.nih.gov/pubmed/16874533

https://link.springer.com/article/10.1007%2Fs00105-006-1180-1

“Cannabinoids for the treatment of chronic refractory pruritus.”  https://www.ncbi.nlm.nih.gov/pubmed/31264498

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist.

Clinical and Experimental Dermatology

“Cannabinoids have been used for their analgesic and euphoric effects for millennia, but recently the antipruritic effects of cannabis have been discovered.

Considering the similarities between pain and itch sensations, we hypothesized that cannabinoid receptors may play a role in the antipruritic effects of cannabinoids.

Our findings support prior researches indicating that cannabinoids exert antipruritic effects. Moreover, our results show that the antipruritic effects of cannabinoids are partially mediated by spinal CB1 receptors.”

https://www.ncbi.nlm.nih.gov/pubmed/29424035

http://onlinelibrary.wiley.com/doi/10.1111/ced.13398/abstract

“antipruritic: 1. Preventing or relieving itching. 2. An agent that relieves itching.”   https://medical-dictionary.thefreedictionary.com/antipruritic

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

Descending serotonergic and noradrenergic systems do not regulate the antipruritic effects of cannabinoids.

Image result for Acta Neuropsychiatrica

“For centuries, cannabinoids have been known to be effective in pain states. Itch and pain are two sensations sharing a lot in common.

OBJECTIVE:

The goal of this research was to observe whether the cannabinoid agonist WIN 55,212-2 reduces serotonin-induced scratching behaviour and whether neurotoxic destruction of descending serotonergic and noradrenergic pathways mediate the antipruritic effect of WIN 55,212-2.

CONCLUSION:

Our findings indicate that cannabinoids dose-dependently reduce serotonin-induced scratching behaviour and neurotoxic destruction of descending inhibitory pathways does not mediate this antipruritic effect.”

https://www.ncbi.nlm.nih.gov/pubmed/27805543

 

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous